Please provide your email address to receive an email when new articles are posted on . Researchers observed significantly longer PFS with ibrutinib plus venetoclax vs. ibrutinib plus placebo. No new ...
SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta ...
Please provide your email address to receive an email when new articles are posted on . Combination ibrutinib and venetoclax remains effective as first-line CLL treatment. Researchers reported 5-year ...
SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting ...
Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients ...
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer Undetectable MRD (uMRD) was assessed by next-generation sequencing at ...
MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical ...
PHILADELPHIA – First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer ...
LBA-2: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study SAN DIEGO, Dec. 12, 2023 ...
The Union Budget 2026-27 signals one of the most comprehensive expansions of India's healthcare vision in recent years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results